Skip to main content

Lacosamide News

New Indication for Motpoly XR (Lacosamide Extended-Release) Capsules for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment)

SILVER SPRING, MD. June 7, 2024/FDA Approvals/ – Today, the U.S. Food and Drug Administration (FDA) approved Aucta Pharmaceuticals Motpoly XR (lacosamide) capsules (100 mg, 150 mg, and 200 mg) for ...

Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy

ATLANTA, Nov. 17, 2020 /PRNewswire/ – UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Seizures, Epilepsy

Related drug support groups

Vimpat

Lacosamide patient information at Drugs.com